Supplementary Table 1: Baseline characteristics of patients included in the current sub analysis, patients excluded, and the interaction of these differences with randomization to digoxin.

Characteristics	Analyzed Cohort (n=980)	Excluded Patients (n=6,818)	p	p Interaction With Randomization to Digoxin
Demographics				
Age	63.4 ± 10.5	64.0 ± 11.0	0.132	0.234
White race	88.60%	85.10%	0.004	0.661
Male	78.60%	74.80%	0.010	0.549
Past Medical History				
Hypertension	43.00%	47.80%	0.005	0.197
Diabetes mellitus	25.40%	28.90%	0.023	0.052
Angina	26.00%	27.30%	0.389	0.899
Prior myocardial infarction	68.40%	62.30%	<0.001	0.483
Physical Examination				
Heart rate	76.5 ± 12.6	78.7 ± 12.6	<0.001	0.511
Systolic blood pressure (mmHg)	126.6 ± 20.2	127.4 ± 20.5	0.235	0.415
Pulmonary crackles	71.00%	71.60%	0.731	0.481
S3 gallop	49.40%	47.90%	0.373	0.145
Edema	50.20%	53.20%	0.077	0.197
Jugular venous distention	52.20%	51.60%	0.719	0.593
Medications (Baseline)				

Prior digoxin	49.90%	42.30%	<0.001	0.053
ACE inhibitor	96.20%	93.00%	<0.001	0.509
Potassium sparing diuretic	11.50%	7.10%	<0.001	0.965
Other diuretic	75.70%	78.40%	0.059	0.696
Nitrates	36.20%	43.10%	<0.001	0.922
Hydralazine	1.00%	1.90%	0.017	0.898
Laboratory Value (baseline)				
eGFR (mL/min/1.73m^2)	70.0 ± 21.7	68.3 ± 24.4	0.038	0.078
Serum creatinine (mg/dL)	1.3 ± 0.4	1.3 ± 0.4	0.148	0.319
Functional Status / Imaging				
Ejection fraction (%)	31.6 ± 12.2	32.0 ± 12.6	0.38	0.969
Preserved ejection fraction (>45%)	11.70%	12.80%	0.338	0.972
Cardio-thoracic ratio	0.51 ± 0.07	0.53 ± 0.07	0.082	0.632
New York Heart Association class	2.1 ± 0.7	2.2 ± 0.7	0.004	0.611

ACE: Angiotensin converting enzyme inhibitor. eGFR: Estimated glomerular filtration rate